SCHEMBL633002

SCHEMBL633002

COc1c(C=CC(=O)c2ccc(O)cc2)ccc(O)c1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.66
CTSL P07711 5/20 0.62
CTSB P07858 5/20 0.62
TDP1 Q9NUW8 1/20 0.62
ABCG2 Q9UNQ0 1/20 0.61
CAPN1 P07384 3/20 0.58
MAOB P27338 1/20 0.58
CHRNA7 P36544 1/20 0.57
DPP4 P27487 3/20 0.55
GABRA3 P34903 1/20 0.55
GABRA2 P47869 1/20 0.55
GABRB2 P47870 1/20 0.55
MAPT P10636 2/20 0.54
P4HB P07237 1/20 0.54
CALM1 P0DP23 1/20 0.54
RAB9A P51151 1/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
F3 P13726 1/20 0.54
XDH P47989 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL633001 1.00 PTPN1 (0.66) PTPN1CTSLCTSBTDP1ABCG2
SCHEMBL29929014 1.00 PTPN1 (0.66) PTPN1CTSLCTSBTDP1ABCG2
SCHEMBL30559523 1.00 PTPN1 (0.66) PTPN1CTSLCTSBTDP1ABCG2
SCHEMBL22014223 0.90 ABCG2 (0.59) PTPN1CTSLCTSBTDP1ABCG2
SCHEMBL20608568 0.89 NPC1 (0.58) PTPN1CTSLCTSBABCG2CAPN1
SCHEMBL23920664 0.87 SNCA (0.68) PTPN1ABCG2DPP4GABRA3GABRA2
SCHEMBL22014224 0.87 CTSL (0.60) PTPN1CTSLCTSBTDP1ABCG2
SCHEMBL7194836 0.87 PTPN1 (0.65) PTPN1CTSLCTSBTDP1ABCG2
SCHEMBL7194832 0.87 PTPN1 (0.65) PTPN1CTSLCTSBTDP1ABCG2
SCHEMBL24208085 0.87 ABCG2 (0.56) PTPN1CTSLCTSBTDP1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
US-12390418-B2 Biphasic compositions comprising one or both of carbonate and phosphate Natural Extraction Systems, LLC (US) 2025-08-19 US disclosed
US-20250009655-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC 2025-01-09 US disclosed
EP-1888174-B1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER (US) 2012-02-22 EP disclosed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270614-A1 Use of chalcones for the treatment of viral disorders HAVCR2, HMGB3, EIF2AK2 PTPN1 2767/4885CTSL 2891/4885CTSB 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.